Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP 4

Novo Nordisk · Phase 3 · Completed · Enrollment 902

NCT03548987

EudraCT 2017-003473-34

ArmPopulationDoseWeeksEstimandWeight change
SemaglutideObesity or overweightn/r20Efficacy-8.3% at week 20
PlaceboObesity or overweightn/r20Efficacy6.5% at week 20
Semaglutide 2.4 mg, in trialObesity or overweight2.4 mg20ITTn/r
Placebo, in trialObesity or overweightn/r20ITTn/r